Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis: A Phase 2a, Single-centered, Randomized, Placebo-controlled, Double-blind, Proof-of-concept Pilot Study.

NCT01670565 is registered in ClinicalTrials.gov with Hospital for Special Surgery, New York as lead sponsor.

NCT NCT01670565
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01670565 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis: A Phase 2a, Single-centered, Randomized, Placebo-controlled, Double-blind, Proof-of-concept Pilot Study.
Lead sponsor
Hospital for Special Surgery, New York
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2012
Completion date
February 29, 2016
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

systemic sclerosis